AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04067128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: Brief telephonic intervention consisting of up to three phone calls
Study NCT04254978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Oral administration
Study NCT00644969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Randomization 2:1 treatment to placebo
Study NCT04529200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electrotherapy treatment
Description: physical therapy management like EMS IFT
Study NCT00644969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline (CP-526,555)
Description: One week of titration up to 1mg bid and 11 weeks of dosing at 1mg bid
Study NCT00099125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00099125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT00099125 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00099125 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02430337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-Assisted SafeCare
Description: A technology-enhanced version of SafeCare
Study NCT02430337 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SafeCare
Description: SafeCare, an evidence-based home visiting program
Study NCT03946735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy as an Effective Treatment for Social Anxiety, Perfectionism, and Rumination
Description: Week one involved introducing CBT and assessing the negative effects of perfectionism, rumination, and social anxiety. Week two allowed participants to specify stressful social activities, stressful social situations, and enjoyable activities. Week three to week six allowed participants to identify automatic thoughts and thinking errors (for example, all or nothing thinking, self-criticism, dysfunctional schemas for self-evaluation, and unrealistic standards). Assignments were provided to participants with the content of exposure to anxiety evoking situations in the treatment sessions and at home. Achievable behavioural goals were set for participants in the treatment sessions and at home.
Study NCT01859494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NINJA 3 Investigational Blood Glucose Monitoring System
Description: Untrained subjects with diabetes self-tested capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.
Study NCT00862186 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 'Fatigue Facts & Fixes'
Description: 'Fatigue Facts \& Fixes' is an evidence based educational resource for adolescents with cancer. It is a bright colored laminated 8.5x11 double sided page. One side features information on cancer-related fatigue: Why am I so tired? (description of cancer-related fatigue); What causes fatigue? (contributing factors - environmental, personal/behavioral, cultural/family/other, and treatment-related); and What can help me to not be so tired? (alleviating factors - environmental, personal/behavioral, cultural/family/other, and treatment-related). The other side is a 'Do Not Disturb' sign with a pillow graphic which adolescents can use in the hospital or at home when they need some quiet time and which may also serve to attract their interest to the resource.
Study NCT00940212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2423
Description: oral, single administration
Study NCT00940212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral administration and single dose
Study NCT02995447 — intervention group
Intervention type: OTHER
Intervention: differences between surface and intracerebral EEG
Description: No intervention is performed. Im- and explantation of intracerebral electrodes is performed for clinical and not for study purposes. The only difference between study and non-study patients is that the surface as well as the intracerebral EEG is recorded and stored in the former, while it is discarded in the latter.
Study NCT03430440 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apply CIPKA mode
Description: The newly developed computer-integrated patient-controlled analgesia (CIPCA) mode increases or decreases the basal infusion rate with the use of the patient's bolus button. Compared with the conventional mode in which only the basal infusion rate is set to be fixed, the CIPCA mode sets the basal infusion rate, the increase / decrease rate of basal rate, and the increment / decrement interval.
Study NCT03897452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl (5 microgram/ml) prediluted ampoules
Description: Bolus; Fentanyl (5 microgram/ml) 0,5 microgram/kg (0.1 ml/kg) is administered over 1 min starting 3-5 min before the lighter skin breaking procedure.~Fentanyl (5 microgram/ml) 2 microgram/kg is administered over 10 min before the start of the more painful procedur ( pleura drainage or tracheal intubation).
Study NCT00912314 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PTNS
Description: Monthly PTNS after 12 weeks of weekly PTNS
Study NCT02292290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: 4 week lead-in 0.6mg Liraglutide OD up to 1.2mg OD after 2 weeks if poor response
Study NCT02292290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: 4 week lead-in 0.6mg Liraglutide OD up to 1.2mg after two weeks if poor response.
Study NCT02292290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylurea or Pioglitazone
Description: Addition to Metformin
Study NCT02292290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide
Description: As per clinical guidelines for prescription
Study NCT03510156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior analytic treatment
Description: Function-based treatment
Study NCT02270164 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artichoke Leaf Extract
Description: Capsule
Study NCT02270164 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study NCT02998801 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IPAD
Description: Patients undergoing surgery will watch the video using an PAD
Study NCT02998801 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VR Goggles
Description: Patients undergoing surgery will watch the video using goggles
Study NCT00424138 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG
Study NCT04458753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar focused exercises
Description: Transersus abdominis activation Multifidus activation Back extension exercise Curl up abdominal exercise
Study NCT03589794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Malaria challenge
Description: Exposure to mosquitoes infected with P. falciparum.
Study NCT03430440 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional mode
Description: PCA pumps typically set a fixed basal infusion rate to set the analgesic to enter at a constant rate every hour (conventional mode).
Study NCT03589794 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Malaria challenge
Description: Exposure to mosquitoes infected with P. falciparum.
Study NCT03589794 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rCSP
Description: The rCSP malaria vaccine is a recombinant full-length P. falciparum circumsporozoite protein comprised of an amino terminus that binds heparin-sulfate proteoglycans, a four-amino-acid repeat region and a carboxy-terminus that contains a thrombospondin-like Type I region domain.
Study NCT01738672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitrous oxide
Description: Administration of nitrous oxide for labor analgesia
Study NCT00565721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluciclatide Injection - (AH111585 (F18))
Description: 18F labelled Cyclic RGD peptide PET agent for injection.
Study NCT03672721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IA Carbo+ Radiation
Description: combination of intraarterial carboplatin + radiation in dose escalation
Study NCT03414216 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 - off-loading in fiberglass cast
Description: As above.
Study NCT02899195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV will be administered before pemetrexed and cisplatin chemotherapy over approximately 60 minutes. Approximately 30 minutes after the durvalumab infusion is complete, pemetrexed 500 mg/m² IV will be administered over 10 minutes. Cisplatin 75 mg/m² IV over 2 hours will begin approximately 30 minutes after the end of pemetrexed administration. If carboplatin is substituted for cisplatin, carboplatin Area Under the Concentration-Time Curve (AUC) 5 will be infused over 30 minutes beginning approximately 15-30 minutes after the end of the pemetrexed administration. Maintenance: On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV over approximately 60 minutes.
Study NCT01921686 — intervention group
Intervention type: OTHER
Intervention: Sample collection and Questionnaire
Description: This is an observational biospecimen collection and questionnaire study. The subjects will be asked to complete a symptom questionnaire at screening visit. In addition, 3 esophageal biopsy samples will be taken to conduct laboratory analyses.
Study NCT02658942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteroscopy
Description: In Group A patients, Karl Storz Flex-X 7.5, FURS with a 365 µm laser fiber.
Study NCT04135599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a non-invasive, safe and easy-to-operate neuro-electrophysiological technique, which becoming an emerging therapeutic option for many mental disorders.It can modulate cortical excitability of target brain region, neuron plasticity and brain connections. Previous studies suggest that tDCS could reduce cue-induced craving and improve cognition in drug addiction.
Study NCT04135599 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a non-invasive, safe and easy-to-operate neuro-electrophysiological technique, which becoming an emerging therapeutic option for many mental disorders.It can modulate cortical excitability of target brain region, neuron plasticity and brain connections. Previous studies suggest that tDCS could reduce cue-induced craving and improve cognition in drug addiction.
Study NCT02949544 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: water immersion
Description: warm water immersion
Study NCT00529152 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Deferiprone
Description: Ferriprox (deferiprone) oral solution will be given orally at a total daily dose of 75 mg/kg body weight or 100 mg/kg body weight, divided into 3 doses, for 24 weeks.
Study NCT01907750 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biliary drainage tube
Study NCT00695422 — intervention group
Intervention type: GENETIC
Intervention: polymerase chain reaction
Description: PCR for HPV DNA detection, performed on specimens collected at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
Study NCT04282343 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The DISCO App
Description: Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist.
Study NCT04282343 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Patients randomized to this arm will receive usual care.
Study NCT02650804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPM31510 Nanosuspension Injection
Study NCT02650804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT03080389 — intervention group
Intervention type: PROCEDURE
Intervention: Extended Urine Culture
Description: Extended Urine Culture Standard cultures will include 0.001 ml of specimen plated on sheep blood agar and MacConkey agar. Plates were inoculated and incubated at 35 degrees Celsius for 24 hours. Samples were considered positive if there were 10\^3 cfu or greater. The extended urine culture will be spun down by centrifuge (3000 rpm for 5 min) and 0.1 ml of the sediment will be cultured for 48 hours.~The participants will fill out the Bother, UDI-6, and PUF questionnaires before the cultures. If a patient has a positive urine culture, the patient will be asked to repeat the questionnaires 7-30 days post treatment with antibiotics. A comparison will be made between the standard and extended urine cultures to assess for a difference in identification and treatment of uropathogens.
Study NCT01712763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix
Description: 180 women will be treated with degarlix 120 mg, in only one administration covering three months
Study NCT01712763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate 11.25 MG/ML (Enantone 11,25)
Description: 180 women will be treated with leuprolide acetate11.25 only once covering three months
Study NCT03490123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R1-Total community treatment with azithromycin
Description: At month 0, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
Study NCT03490123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R1-Total community treatment with azithromycin
Description: At month 0, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
Study NCT03490123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R2-Total community treatment with azithromycin
Description: At month 6, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
Study NCT03490123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R3-Total community treatment with azithromycin
Description: At month 12, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
Study NCT03490123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R2-Total targeted treatment with azithromycin
Description: At 6 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
Study NCT03490123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R3-Total targeted treatment with azithromycin
Description: At 12 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
Study NCT03240003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GC-MRT
Description: Group 1 will receive a 4-week (8-sessions) course of GC-MRT
Study NCT03240003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified GC-MRT
Description: group 3 will receive a 4-week (8-sessions) course of GC-MRT, modified
Study NCT03240003 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-GC-MRT
Description: Group 2 will receive a 4-week (8-sessions) course of non-GC-MRT
Study NCT01064973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arbaclofen
Description: A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the oral OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
Study NCT02087085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 µg Brimonidine Implant
Description: 400 µg brimonidine implant in the study eye using Brimo DDS® applicator on Day 1, and every 3 months through Month 21.
Study NCT02087085 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham treatment with needleless applicator (no implant) to the study eye on Day 1, and every 3 months through Month 21.
Study NCT04252872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP0605
Study NCT04252872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1405
Study NCT04252872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1401
Study NCT00695422 — intervention group
Intervention type: OTHER
Intervention: cytology specimen collection procedure
Description: Detection of HPV-associated neoplasia at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
Study NCT00695422 — intervention group
Intervention type: OTHER
Intervention: histological technique
Description: Detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
Study NCT00695422 — intervention group
Intervention type: PROCEDURE
Intervention: colposcopic biopsy
Description: Where observed during HRA, collection of tissue for detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
Study NCT05659472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination mindfulness spiritual-based cognitive therapy plus hypnosis
Description: The intervention was divided into eight components in eight sessions, namely (1) psychoeducation and intention, (2) awareness of breathing mindfulness, (3) body scan, (4) comfort training through daily activity/comfort exercises, (5) self-compassion / having a great soul with acceptance, gratitude, and sincerity, (6) planning happiness through independent healthy behavior targets, (7) independent healthy behavior (8) independent healthy behavior evaluation. Each therapeutic component of each session is further divided into three sub-components, namely psychoeducation, training, and hypnosis.
Study NCT05659472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy
Description: The program curriculum consists of the automatic pilot; living in our heads; gathering the scattered mind; recognizing aversion; allowing and letting be; thoughts as thoughts; kindness in action; maintaining and extending new learning.
Study NCT02658942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shockwave lithotripsy
Description: In Group B patients, a Siemens Lithostar Lithotriptor
Study NCT02503787 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Spinal Cord Stimulation (SCS)
Description: SCS programming options
Study NCT01121081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alga Dunaliella Bardawil
Description: 4 capsules per day, 2 in the morning 2 in the evening for 3 month
Study NCT01121081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Alga Dunaliella Bardawil~4 capsules per day, 2 in the morning 2 in the evening for 3 month
Study NCT03831204 — intervention group
Intervention type: DEVICE
Intervention: biopac
Description: Acoustic cardiography was performed for all participants using the BIOPAC system with Student Lab software version 3.7.2. An electrocardiogram was obtained by two electrodes placed at the right upper limb and the lower left limb. Simultaneously heart sounds were recorded with a specific sensor placed at the mitral focus.
Study NCT03831204 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: prognostic scores
Description: Effect and GWTGHF were calculated for every patient
Study NCT03026998 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: MRI will be performed each year during 10 years.
Study NCT03068728 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Arista
Study NCT03068728 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nexfoam
Study NCT03068728 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nasopore
Study NCT03552848 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: MSC at a dose of 1000000 cells per kilogram of body weight will be given intravenously once every 4 days for 4 times